Logo image of ATNF

180 LIFE SCIENCES CORP (ATNF) Stock Fundamental Analysis

NASDAQ:ATNF - US68236V3024 - Common Stock

7.04 USD
-0.57 (-7.49%)
Last: 8/15/2025, 8:06:05 PM
7.29 USD
+0.25 (+3.55%)
After Hours: 8/15/2025, 8:06:05 PM
Fundamental Rating

1

Taking everything into account, ATNF scores 1 out of 10 in our fundamental rating. ATNF was compared to 542 industry peers in the Biotechnology industry. ATNF has a bad profitability rating. Also its financial health evaluation is rather negative. ATNF is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ATNF had negative earnings in the past year.
In the past year ATNF has reported a negative cash flow from operations.
In the past 5 years ATNF always reported negative net income.
In the past 5 years ATNF always reported negative operating cash flow.
ATNF Yearly Net Income VS EBIT VS OCF VS FCFATNF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

The Return On Assets of ATNF (-160.70%) is worse than 86.16% of its industry peers.
The Return On Equity of ATNF (-319.99%) is worse than 71.77% of its industry peers.
Industry RankSector Rank
ROA -160.7%
ROE -319.99%
ROIC N/A
ROA(3y)-229.08%
ROA(5y)-148.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ATNF Yearly ROA, ROE, ROICATNF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5K -5K 10K 15K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ATNF so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATNF Yearly Profit, Operating, Gross MarginsATNF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

1

2. Health

2.1 Basic Checks

Compared to 1 year ago, ATNF has more shares outstanding
ATNF has more shares outstanding than it did 5 years ago.
ATNF has a better debt/assets ratio than last year.
ATNF Yearly Shares OutstandingATNF Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
ATNF Yearly Total Debt VS Total AssetsATNF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

ATNF has an Altman-Z score of -16.49. This is a bad value and indicates that ATNF is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -16.49, ATNF is not doing good in the industry: 80.69% of the companies in the same industry are doing better.
ATNF has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
ATNF has a Debt to Equity ratio of 0.12. This is in the lower half of the industry: ATNF underperforms 64.66% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Altman-Z -16.49
ROIC/WACCN/A
WACCN/A
ATNF Yearly LT Debt VS Equity VS FCFATNF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M 100M

2.3 Liquidity

A Current Ratio of 0.58 indicates that ATNF may have some problems paying its short term obligations.
ATNF has a worse Current ratio (0.58) than 91.99% of its industry peers.
A Quick Ratio of 0.58 indicates that ATNF may have some problems paying its short term obligations.
ATNF has a Quick ratio of 0.58. This is amonst the worse of the industry: ATNF underperforms 91.62% of its industry peers.
Industry RankSector Rank
Current Ratio 0.58
Quick Ratio 0.58
ATNF Yearly Current Assets VS Current LiabilitesATNF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 54.65% over the past year.
EPS 1Y (TTM)54.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3125%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
ATNF is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 80.13% yearly.
EPS Next Y0%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year54.15%
Revenue Next 2Y91.35%
Revenue Next 3Y90.65%
Revenue Next 5Y80.13%

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
ATNF Yearly Revenue VS EstimatesATNF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M
ATNF Yearly EPS VS EstimatesATNF Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -100 -200 -300

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ATNF. In the last year negative earnings were reported.
Also next year ATNF is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATNF Price Earnings VS Forward Price EarningsATNF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATNF Per share dataATNF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ATNF does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

180 LIFE SCIENCES CORP

NASDAQ:ATNF (8/15/2025, 8:06:05 PM)

After market: 7.29 +0.25 (+3.55%)

7.04

-0.57 (-7.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11
Earnings (Next)11-12 2025-11-12
Inst Owners1.07%
Inst Owner Change24.45%
Ins Owners28.84%
Ins Owner Change116.64%
Market Cap42.52M
Analysts82.86
Price TargetN/A
Short Float %286.32%
Short Ratio0.67
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.9
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-12.78
EYN/A
EPS(NY)-3.06
Fwd EYN/A
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)-0.52
OCFYN/A
SpS0
BVpS0.89
TBVpS-0.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -160.7%
ROE -319.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-229.08%
ROA(5y)-148.25%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.58
Quick Ratio 0.58
Altman-Z -16.49
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3125%
EPS Next Y0%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year54.15%
Revenue Next 2Y91.35%
Revenue Next 3Y90.65%
Revenue Next 5Y80.13%
EBIT growth 1Y27.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y76.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y76.64%
OCF growth 3YN/A
OCF growth 5YN/A